Jefferies analyst Akash Tewari initiated coverage with a Buy rating on Third Harmonic Bio, Inc. (THRD – Research Report) today and set a price target of $30.00. The company’s shares opened today at $20.36.
According to TipRanks, Tewari is a 5-star analyst with an average return of 19.7% and a 53.73% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Horizon Therapeutics, Regeneron, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Third Harmonic Bio, Inc. with a $32.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $21.49 and a one-year low of $16.00. Currently, Third Harmonic Bio, Inc. has an average volume of 285.2K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of THRD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company’s lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Read More on THRD:
